Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch

Business Of Biotech

We love to hear from our listeners. Send us a message.

As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O" RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Kapitel

1. Circular RNA Biotech Innovations (00:00:00)

2. Innovations in RNA-based Gene Editing (00:07:59)

3. Advantages of Circular RNA in Biotech (00:13:59)

4. Innovating With Novel Technology Risks (00:22:22)

5. Emerging RNA Cell Therapy Potential (00:28:57)

6. RNA Platform Strategies and Partnerships (00:42:20)

7. Exploring the Future of RNA Therapies (00:48:49)